Fate Therapeutics Aktie
WKN DE: A1W50M / ISIN: US31189P1021
17.03.2014 22:12:30
|
Fate Therapeutics Q4 Loss Widens - Quick Facts
(RTTNews) - Fate Therapeutics Inc. (FATE) posted fourth-quarter net loss and comprehensive loss of $5.7 million, wider than $4.2 million last year. Loss per share for the latest fourth quarter narrowed to $0.29 per share from $3.51 per share in the comparable quarter last year.
On average, three analysts polled by Thomson Reuters expected the company to report a loss of $0.27 per share.
The company did not have revenues for the fourth quarter of 2013. Total revenues for the fourth quarter of 2012 were $0.6 million.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Fate Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Fate Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Fate Therapeutics Inc | 0,82 | -7,14% |
|